Claims for Patent: 6,376,242

Summary for Patent: 6,376,242

Title:	Methods and compositions for treating platelet-related disorders using MPL pathway inhibitory agents
Abstract:	The invention relates to the treatment of subjects for the purpose inhibiting vaso-occlusive events, including thrombosis and embolism, by administering agents which reduce the number of circulating platelets to low or below normal levels. Methods and pharmaceutical preparations comprising such agents are provided.
Inventor(s):	Hanson; Stephen R. (Stone Mountain, GA)
Assignee:	Emory University (Atlanta, GA)
Application Number:	09/666,224
Patent Claims:	1. A method for treating a subject to inhibit a vase-occlusive event comprising administering to the subject an MPL pathway inhibitory agent in an amount effective to reduce platelet count in the subject to a low normal level. 2. The method of claim 1, wherein the vaso-occlusive event is an occlusion of a stent or an occlusion of a blood vessel. 3. The method of claim 1, wherein the vaso-occlusive event is intimal hyperplasia. 4. The method of claim 1, wherein the vaso-occlusive event is a thrombotic event. 5. The method of claim 1, wherein the subject does not have a hematological proliferative disorder. 6. The method of claim 1, wherein the subject is apparently healthy. 7. The method of claim 1, wherein the subject exhibits symptoms of a vaso-occlusive event. 8. The method of claim 1, wherein the subject has a normal platelet count. 9. The method of claim 1, wherein the subject has an abnormally elevated risk of a thrombotic event. 10. The method of claim 1, wherein the subject has vascular disease. 11. The method of claim 1, wherein the subject has had a primary vaso-occlusive event. 12. The method of claim 1, wherein the subject has a condition selected from the group consisting of hypercholesterolemia, hypertension and atherosclerosis. 13. The method of claim 1, wherein the subject will undergo an elective surgical procedure. 14. The method of claim 1, wherein platelet count is reduced by at least 20%. 15. The method of claim 1, wherein platelet count is reduced to below 250.times.10.sup.3 platelets per .mu.l. 16. The method of claim 1, wherein the MPL inhibitory agent is administered with an agent for treating vascular disorder or vascular complication. 17. The method of claim 1, wherein the MPL inhibitory agent binds to an MPL receptor. 18. The method of claim 1, wherein the MPL inhibitory agent binds to a thrombopoietin molecule. 19. The method of claim 1, wherein the platelet count is reduced to below normal levels. 20. The method of claim 4, wherein the thrombotic event is a thromboembolic event. 21. The method of claim 4, wherein the thrombotic event is a primary thrombotic event. 22. The method of claim 4, wherein the thrombotic event is a secondary thrombotic event. 23. The method of claim 4, wherein the thrombotic event is selected from the group consisting of arterial thrombosis, coronary thrombosis, venous thrombosis, microvascular thrombosis, stent thrombosis, graft thrombosis and heart valve thrombosis. 24. The method of claim 4, wherein the vaso-occlusive event is selected from the group consisting of myocardial infarction, stroke, transient ischemio attack and coronary stenosis. 25. The method of claim 1, wherein the subject is a human. 26. The method of claim 10, wherein tho vascular disease is selected from the group consisting of arteriosclerosis, cardiovascular disease, cerebrovascular disease, renovascular disease, mesenteric vascular disease, pulmonary vascular disease, ocular vascular disease and peripheral vascular disease. 27. The method of claim 1, wherein the subject has undergone a surgical procedure. 28. The method of claim 13, wherein the surgical procedure is selected from the group consisting of coronary angiography, coronary stent placement, coronary by-pass surgery, carotid artery procedure, peripheral stent placement, vascular grafting, thrombectomy, peripheral vascular surgery, vascular surgery, organ transplant, artificial heart transplant, vascular angioplasty, vascular laser therapy, vascular replacement and vascular stenting. 29. The method of claim 28, wherein the surgical procedure is selected from the group consisting of coronary angiography, coronary stent placement, coronary by-pass surgery, carotid artery procedure, peripheral stent placement, vascular grafting, thrombectomy, peripheral vascular surgery, vascular surgery, organ transplant, artificial heart transplant, vascular angloplasty, vascular laser therapy, vascular replacement and vascular stenting. 30. The method of claim 1, wherein the effective amount is in the rage of 0.001 mg/kg/day to 30 mg/kg/day. 31. The method of claim 1, wherein platelet count is reduced by at least 50%. 32. The method of claim 1, wherein platelet count is reduced to below 200.times.10.sup.3 platelets per .mu.l. 33. The method of claim 1, wherein platelet count is reduced to below 150.times.10.sup.3 platelets per .mu.l. 34. The method of claim 1, wherein platelet count is reduced to below 100.times.10.sup.3 platelets per .mu.l. 35. The method of claim 1, wherein platelet count is reduced by at least 10% and to below 200.times.10.sup.3 platelets per .mu.l. 36. The method of claim 16, wherein the agent for treating vascular disorder or vascular complication is an anti-thrombotic agent. 37. The method of claim 36, wherein the anti-thrombotic agent is selected from the group consisting of anti-coagulant agents, fibrinolytic agents and inhibitors of platelet function. 38. The method of claim 37, wherein the inhibitors of platelet function are selected from the group consisting of aspirin, abciximab, clopidogrel and dipyridamole. 39. The method of claim 37, wherein the anti-coagulant agents are selected from the group consisting of glycosoaminoglycans and vitamin K antagonists. 40. The method of claim 37, wherein the fibrinolytic agents are selected from the group consisting of plasminogen activators, plasmin and plasminogen. 41. The method of claim 40, wherein the plasminogen activators are selected from the group consisting of tissue plasminogen activator (TPA), streptokinase and urokinase. 42. The method of claim 13, wherein the MPL inhibitory agent is administered prior to the elective surgery. 43. The method of claim 1, wherein the MPL inhibitory agent is administered by a parenteral route. 44. The method of claim 1, wherein the MPL inhibitory agent is administered by an enteral route. 45. The method of claim 1, wherein the MPL inhibitory agent is administered in a sustained release device. 46. The method of claim 11, wherein the MPL inhibitory agent is administered following the primary vaso-occlusive event. 47. The method of claim 16, wherein the agent for treating vascular disorder or vascular complication is selected from the group consisting of anti-inflammatory agents, anti-thrombotic agents, anti-platelet agents, fibrinolytic agents, lipid reducing agents, direct thrombin inhibitors, glycoprotein IIb/IIIa receptor inhibitors, agents that binds to cellular adhesion molecules and inhibit the ability of white blood cells to attach to such molecules, calcium channel blockers, beta-adrenergic receptor blockers, cyclooxygenase-2 inhibitors, and angiotensin system inhibitors.

Details for Patent 6,376,242

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Microbix Biosystems Inc.	KINLYTIC	urokinase	For Injection	021846	01/16/1978		2039-02-26
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2039-02-26